Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)
Mandate

Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)

January 20, 2023 Banking and Finance

Vinge has advised Sandvik AB (publ) and Sandvik Treasury AB (publ) in connection with the entry into of a EUR 500 million loan agreement with the European Investment Bank (EIB). The loan will support Sandvik’s investments in research and development (R&D), which include advanced solutions in component manufacturing as well as solutions for electrification and automation in mining and infrastructure.

The loan has a seven-year tenor and will support Sandvik’s R&D investment plans until 2025.

Sandvik is a global, high-tech engineering group providing solutions that enhance productivity, profitability and sustainability for the manufacturing, mining and infrastructure industries.

Vinge’s team consisted of Albert Wållgren, Arvid Weimers and Karl-Gustaw Tobola.

Related

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

 Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.
May 30, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).
May 28, 2024

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

 On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.
May 28, 2024